# Safety and Immunogenicity of New Malaria Vaccine Candidate ChAd63 CS Administered Alone and With MVA CS

> **NCT01450280** · PHASE1 · COMPLETED · sponsor: **University of Oxford** · enrollment: 24 (actual)

## Conditions studied

- Malaria

## Interventions

- **BIOLOGICAL:** ChAd63 CS
- **BIOLOGICAL:** ChAd63 CS, MVA CS
- **BIOLOGICAL:** ChAd63 CS
- **BIOLOGICAL:** ChAd63, MVA CS

## Key facts

- **NCT ID:** NCT01450280
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2012-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01450280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01450280, "Safety and Immunogenicity of New Malaria Vaccine Candidate ChAd63 CS Administered Alone and With MVA CS". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01450280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*